James L Gulley Selected Research

Fatigue

1/2021	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
1/2018	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
1/2018	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
1/2017	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
6/2013	Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James L Gulley Research Topics

Disease

187	Neoplasms (Cancer) 11/2023 - 01/2003
140	Prostatic Neoplasms (Prostate Cancer) 11/2023 - 01/2003
28	Carcinoma (Carcinomatosis) 01/2023 - 02/2005
27	Disease Progression 10/2023 - 05/2004
19	Vaccinia 05/2023 - 02/2005
19	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2004
14	Fowlpox 05/2023 - 02/2005
11	Melanoma (Melanoma, Malignant) 01/2023 - 12/2010
10	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 01/2013
10	Breast Neoplasms (Breast Cancer) 01/2021 - 06/2006
8	Chordoma 01/2024 - 11/2015
7	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 10/2015
6	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 10/2013
5	Fatigue 01/2021 - 06/2013
4	COVID-19 01/2021 - 01/2020
4	Merkel Cell Carcinoma 01/2020 - 01/2017
3	Injection Site Reaction 01/2023 - 03/2014
3	Urogenital Neoplasms 01/2023 - 01/2020
3	Squamous Cell Carcinoma of Head and Neck 01/2023 - 01/2020
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 01/2016
3	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 06/2009
3	Human Influenza (Influenza) 01/2021 - 02/2014
3	Myositis (Idiopathic Inflammatory Myopathies) 01/2019 - 01/2017
2	Kidney Neoplasms (Kidney Cancer) 01/2023 - 01/2020
2	Necrosis 01/2023 - 01/2019
2	Lymphopenia (Lymphocytopenia) 01/2023 - 11/2020
2	Inflammation (Inflammations) 01/2022 - 09/2020
2	Circulating Neoplastic Cells 01/2021 - 01/2017

Drug/Important Bio-Agent (IBA)

97	VaccinesIBA 05/2023 - 08/2003
42	AntigensIBA 11/2023 - 08/2003
42	Immune Checkpoint InhibitorsIBA 01/2023 - 08/2011
36	Cancer VaccinesIBA 01/2023 - 05/2005
32	PROSTVACIBA 10/2023 - 07/2009
32	AndrogensIBA 05/2023 - 01/2003
31	Prostate-Specific Antigen (Semenogelase)IBA 05/2023 - 08/2003
30	avelumabIBA 01/2023 - 10/2015
23	sipuleucel-T (APC8015)FDA Link 01/2023 - 01/2010
20	Docetaxel (Taxotere)FDA Link 01/2021 - 01/2003
17	Proteins (Proteins, Gene)FDA Link 03/2024 - 10/2007
17	IpilimumabIBA 11/2020 - 02/2007
15	Monoclonal AntibodiesIBA 01/2023 - 02/2007
13	B7-H1 AntigenIBA 01/2023 - 07/2017
11	Biomarkers (Surrogate Marker)IBA 03/2024 - 05/2004
11	LigandsIBA 03/2024 - 10/2012
10	CytokinesIBA 11/2023 - 02/2009
10	Immunoglobulin G (IgG)IBA 01/2023 - 01/2011
10	Brachyury protein (Brachyury)IBA 01/2021 - 10/2015
9	NivolumabIBA 01/2023 - 12/2014
9	Carcinoembryonic AntigenIBA 11/2015 - 08/2003
8	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 02/2005
8	PlatinumIBA 10/2020 - 01/2017
8	Thalidomide (Thalomid)FDA Link 04/2010 - 01/2003
7	Interleukin-12 (IL 12)IBA 01/2023 - 10/2015
7	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 10/2007
7	Prednisone (Sone)FDA LinkGeneric 01/2021 - 02/2009
7	Hormones (Hormone)IBA 03/2009 - 07/2005
6	enzalutamideIBA 10/2023 - 01/2020
6	pembrolizumabIBA 01/2023 - 01/2017
6	Testosterone (Sustanon)FDA Link 01/2022 - 05/2004
6	Peptides (Polypeptides)IBA 08/2016 - 08/2003
6	EpitopesIBA 01/2013 - 08/2003
6	VA 061 (VA061)IBA 01/2008 - 01/2003
5	Transcription Factors (Transcription Factor)IBA 01/2021 - 11/2015
5	AntibodiesIBA 10/2020 - 01/2019
4	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2024 - 01/2019
4	FluoridesIBA 10/2023 - 11/2018
4	Bevacizumab (Avastin)FDA Link 11/2022 - 02/2009
4	Programmed Cell Death 1 ReceptorIBA 01/2022 - 01/2018
4	SteroidsIBA 01/2021 - 12/2018
4	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 03/2010
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2023 - 08/2016
3	Interleukin-15 (Interleukin 15)IBA 11/2023 - 09/2017
3	prostatic acid phosphataseIBA 01/2023 - 01/2017
3	Lipase (Acid Lipase)FDA Link 01/2023 - 01/2018
3	AutoantigensIBA 01/2022 - 01/2006
3	cabozantinibIBA 01/2021 - 01/2020
3	smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicIBA 01/2021 - 08/2019
3	Androgen Antagonists (Antiandrogens)IBA 01/2019 - 03/2005
3	Lenalidomide (CC 5013)FDA Link 10/2016 - 03/2004
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 09/2015 - 02/2005
3	Gonadotropin-Releasing Hormone (GnRH)FDA Link 10/2013 - 05/2005
3	Diphosphonates (Bisphosphonates)IBA 02/2009 - 01/2007
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2023 - 12/2018
2	talimogene laherparepvecIBA 01/2023 - 01/2018
2	Histones (Histone)IBA 01/2023 - 01/2019
2	Amylases FDA Link 01/2023 - 01/2017
2	CalciumIBA 01/2022 - 09/2007
2	Axitinib (AG 013736)IBA 01/2022 - 01/2020
2	Sunitinib (Sutent)FDA Link 01/2022 - 10/2013
2	Therapeutic UsesIBA 01/2022 - 01/2018
2	durvalumabIBA 12/2021 - 12/2018
2	olaparibIBA 12/2021 - 12/2018

Therapy/Procedure

111	Therapeutics 11/2023 - 05/2003
90	Immunotherapy 01/2024 - 01/2006
53	Castration 11/2023 - 04/2004
28	Drug Therapy (Chemotherapy) 01/2022 - 02/2006
18	Radiotherapy 05/2023 - 05/2003
5	Aftercare (After-Treatment) 01/2023 - 01/2020
4	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 01/2019
3	Intravenous Infusions 10/2019 - 01/2018